Yuanqiang Wang

Dr. Yuanqiang Wang


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2019 in Molecules
Verified
Journal Article
Open access
PDF file
YWYuanqiang Wang
Yuanqiang Wang
HGHaiqiong Guo
Haiqiong Guo
ZFZHIWEI FENG
ZHIWEI FENG
SWSiyi Wang
Siyi Wang
YWYuxuan Wang
Yuxuan Wang
HLHua zhi Lin
Hua zhi Lin
The blockade of the programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) pathway plays a critical role in cancer immunotherapy by reducing the immune escape. Five monoclonal antibodies that antagonized PD-1/PD-L1 interaction have been approved by the Food and Drug Administration (FDA) and marketed as immunotherapy for cancer treatment. However, some weaknesses of antibodies, such as high cost, low stability, poor amenability for oral administration, and immunogenicity, should not be overlooked. To overcome these disadvantages, small-molecule inhibitors targeting PD-L1 were developed. In the present work, we applied in silico and in vitro approaches to develop short peptides targeting PD-1 as chemical probes for the inhibition of PD-1–PD-L1 interaction. We first predicted the potential binding pocket on PD-1/PD-L1 protein–protein interface (PPI). Sequentially, we carried out virtual screening against our in-house peptide library to identify potential ligands. WANG-003, WANG-004, and WANG-005, three of our in-house peptides, were predicted to bind to PD-1 with promising docking scores. Next, we conducted molecular docking and molecular dynamics (MD) simulation for the further analysis of interactions between our peptides and PD-1. Finally, we evaluated the affinity between peptides and PD-1 by surface plasmon resonance (SPR) binding technology. The present study provides a new perspective for the development of PD-1 inhibitors that disrupt PD-1–PD-L1 interactions. These promising peptides have the potential to be utilized as a novel chemical probe for further studies, as well as providing a foundation for further designs of potent small-molecule inhibitors targeting PD-1.

18 September 2019 in Molecules
Verified
Journal Article
Open access
PDF file
LWLujing Wang
Lujing Wang
MLMin Liu
Min Liu
FYFei Yin
Fei Yin
YWYuanqiang Wang
Yuanqiang Wang
XLXingan Li
Xingan Li
JLJianhui Liu
Jianhui Liu
Studies have indicated that Na+-d-glucose co-transporter (SGLT) inhibitors had anti-proliferative activity by attenuating the uptake of glucose in several tumor cell lines. In this study, the molecular docking showed that, trilobatin, one of the dihydrochalcones from leaves of Lithocarpus polystachyus Rehd., might be a novel inhibitor of SGLT1 and SGLT2, which evidently attenuated the uptake of glucose in vitro and in vivo. To our surprise, we observed that trilobatin did not inhibit, but promoted the proliferation of human hepatoblastoma HepG2 and Huh 7 cells when it was present at high concentrations. At the same time, incubation with high concentrations of trilobatin arrested the cell cycle at S phase in HepG2 cells. We also found that treatment with trilobatin had no significant effect on the expression of hepatitis B x-interacting protein (HBXIP) and hepatocyte nuclear factor (HNF)-4α, the two key regulators of hepatocyte proliferation. Taken together, although trilobatin worked as a novel inhibitor of SGLTs to attenuate the uptake of glucose, it also selectively induced the cell proliferation of HepG2 cells, suggesting that not all the SGLT inhibitors inhibited the proliferation of tumor cells, and further studies are needed to assess the anti-cancer potentials of new glucose-lowering agents.

12 November 2020 in New Journal of Chemistry
Verified
Journal Article
Closed access
PDF file
HCHan Chu
Han Chu
QHQing-Xiu He
Qing-Xiu He
JWJuan Wang
Juan Wang
YHYong Hu
Yong Hu
YWYuanqiang Wang
Yuanqiang Wang
HLHua zhi Lin
Hua zhi Lin
Histone deacetylase 6 (HDAC6) can deacetylate many substrates, including α-tubulin, cortactin, and HSP90α. This makes HDAC6 an interesting, emerging target. In this study, we selected 52 benzohydroxamate-based compounds and conducted 3D-QSAR studies using CoMFA and CoMSIA models. The results showed that CoMFA (n = 9; q2 = 0.556; r2 = 0.998) and CoMSIA (n = 9; q2 = 0.656; r2 = 0.996) have robust stability and predictability. The contour maps of the steric field, hydrophobic field, and hydrogen-bond donor field revealed the modified regions of these compounds. Subsequently, molecular docking was used to explore the docking mode of compounds and receptors. Based on these results, we designed 11 new benzohydroxamate-based compounds and predicted their activity and ADME/T properties. The results indicated that these compounds have strong pharmaceutical properties, and MD simulation analysis confirmed that Asp742 and His610 in the active site played a key role in this. Overall, these results serve as an important reference for the discovery and design of new HDAC6 inhibitors.

3 May 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
PLPingPing Long
PingPing Long
SLSiyu Li
Siyu Li
LPLingyun Pan
Lingyun Pan
YWYuanqiang Wang
Yuanqiang Wang
WCWanyi Chen
Wanyi Chen
XWXiaoxiao Wang
Xiaoxiao Wang
Objective: As a novel drug formulation, antibody drug conjugates (ADCs) are widely used in various types of cancer. However, clinically, there is a lack of attention to the CVD produced by them, as well as a lack of research on the real-world situation. Using the Food and Drug Administration Adverse Event Reporting System (FAERS) database, to ensure its clinical safety application, we analyzed post-marketing data on antitumor ADCs to identify risk factors and drugs associated with the risk of cardiovascular events.Research design and methods: We used OpenVigil 2.1 to conduct a database query for adverse events (AEs) reported to the FAERS database between the time the drug was launched and the second quarter of 2023. Cardiovascular adverse events (AEs) were grouped into fourteen narrow categories using the Standardized Medical Dictionary for Regulatory Activities (MedDRA) Queries (SMQs), and the reporting odds ratio (ROR) and the proportional reporting ratio (PRR) for reporting the association between different drugs and cardiovascular disease (CVD) risk were calculated.Results: In the FAERS database, 1863 AEs associated with CVD we studied were identified in patients receiving ADC therapy. Most reports came from people aged ≥65, but a significant number of cases were found to be unknown. The number of patients with antibody-drug conjugates (ADCs)-related CVD cases aged <18 years, 18–64 years, and≥ 65 years was 52 (2.79%), 586 (31.45%), and 613 (32.90%), respectively. The proportion of female patients (834, 44.77%) was higher than that of male patients (752, 40.37%). Death (770 reports), disability (9 reports), Hospitalization initial or prolonged (407 reports), and life-threatening reactions (187 reports). Of the 770 deaths reported, 103 (31.7%) were associated with brentuximab vedotin, 10 (24.4%) with sacituzumab govitecan, 22 (19.3%) with enfortumab vedotin, and 35 (34.7%) with trastuzumab emtansine.49 (41.2%) cases were associated with polatuzumab vedotin, 62 (29%) with trastuzumab deruxtecan, 423 (54.3%) with gemtuzumab ozogamicin, and 66 (38.8%) with inotuzumab ozogamicin. In a disproportionate number of SMQS, cardiac failure (n = 277) and embolic and thrombotic events, venous (n = 446) were the most frequently reported CVD-related AEs in ADCs.Conclusion: By mining the FAERS database, we provided relevant information on the association between ADC use and cardiovascular-associated AEs. ADCs were associated with increased cardiovascular toxicity, deserving distinct monitoring and appropriate management. Further research is needed to confirm these findings and assess causality.

9 January 2015 in Molecules
Verified
Journal Article
Open access
PDF file
RYRui Yu
Rui Yu
JWJuan Wang
Juan Wang
RWRui Wang
Rui Wang
YLYong Lin
Yong Lin
YHYong Hu
Yong Hu
HLHua zhi Lin
Hua zhi Lin
The mitochondrial cytochrome P450 enzymes inhibitor steroid 11β-hydroxylase (CYP11B1) can decrease the production of cortisol. Therefore, these inhibitors have an effect in the treatment of Cushing’s syndrome. A pharmacophore model generated by Genetic Algorithm with Linear Assignment for Hypermolecular Alignment of Datasets (GALAHAD) was used to align the compounds and perform comparative molecular field analysis (CoMFA) with Q2 = 0.658, R2 = 0.959. The pharmacophore model contained six hydrophobic regions and one acceptor atom, and electropositive and bulky substituents would be tolerated at the A and B sites, respectively. A three-dimensional quantitative structure-activity relationship (3D-QSAR) study based on the alignment with the atom root mean square (RMS) was applied using comparative molecular field analysis (CoMFA) with Q2 = 0.666, R2 = 0.978, and comparative molecular similarity indices analysis (CoMSIA) with Q2 = 0.721, R2 = 0.972. These results proved that all the models have good predictability of the bioactivities of inhibitors. Furthermore, the QSAR models indicated that a hydrogen bond acceptor substituent would be disfavored at the A and B groups, while hydrophobic groups would be favored at the B site. The three-dimensional (3D) model of the CYP11B1 was generated based on the crystal structure of the CYP11B2 (PDB code 4DVQ). In order to probe the ligand-binding modes, Surflex-dock was employed to dock CYP11B1 inhibitory compounds into the active site of the receptor. The docking result showed that the imidazolidine ring of CYP11B1 inhibitors form H bonds with the amino group of residue Arg155 and Arg519, which suggested that an electronegative substituent at these positions could enhance the activities of compounds. All the models generated by GALAHAD QSAR and Docking methods provide guidance about how to design novel and potential drugs for Cushing’s syndrome treatment.

1 June 2019 in Computational Biology and Chemistry
Verified
Journal Article
Closed access
WYWang Yuxuan
Wang Yuxuan
HGHaiqiong Guo
Haiqiong Guo
GTGuanghui Tang
Guanghui Tang
QHQingxiu He
Qingxiu He
YZYuping Zhang
Yuping Zhang
HLHua zhi Lin
Hua zhi Lin